SARS-CoV-2 is an enveloped positive-sense RNA virus and it's the 7th coronavirus which can infect human causing disease ranging from mild common cold, fever, dry cough, fatigue, shortness of breath and severe respiratory failure.
SARS-CoV-2 testing may be incorporated as part of a comprehensive approach to reducing transmission. Symptom screening, testing, and contact tracing are strategies to identify people infected with SARS-CoV-2 so that actions can be taken to slow and stop the spread of the virus.
Various categories of in vitro diagnostic tests are used to detect SARS-CoV-2: Viral tests, including nucleic acid amplification tests (NAATs) and antigen tests are used as diagnostic tests to detect infection with SARS-CoV-2 which is important to patient isolation, management and treatment. Antibody tests (Serology tests) are widely used in the previous SARS-CoV-2 infection detection and aid in the diagnosis of current SARS-CoV-2 infection combined with PCR, clinical symptoms, risk factors or a chest CT scan.
is an in vitro real-time Reverse Transcriptase (RT) PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2, the virus causing COVID-19, in oropharyngeal swabs and sputum specimens from individuals. The specimens of this test from either the upper or lower respiratory tract.
 WHO. Clinical management of severe acute respiratory infection when COVID-19 is suspected external icon. 13 March 2020.
 CDC. Overview of Testing for SARS-CoV-2 (COVID-19). Mar. 17, 2021